Ann Lab Med.  2017 Sep;37(5):415-419. 10.3343/alm.2017.37.5.415.

Characterization of Extended-Spectrum β-Lactamase Genes of Shigella flexneri Isolates With Fosfomycin Resistance From Patients in China

• Liu Y
• Cheng Y
• Yang H
• Hu L
• Cheng J
• Ye Y
• Li J

• KMID: 2383917
• DOI: http://doi.org/10.3343/alm.2017.37.5.415

Abstract

BACKGROUND
The emergence of fosfomycin resistance and extended-spectrum β-lactamase (ESBL) genes is a serious threat to public health and a new challenge in shigellosis treatment. The purpose of this study was to identify fosfomycin resistance and characterize β-lactamase genes in fos-carrying isolates of Shigella flexneri from patients in China.
METHODS
A total of 263 S. flexneri isolates were collected from 34 hospitals in the Anhui Province of China during September 2012-September 2015 and screened for fosA3, fosA, and fosC2 by PCR amplification and sequencing. The fos-carrying isolates were then screened for β-lactamase genes. The clonal relationships between fosA3-carrying isolates, the transmissibility of fosfomycin resistance, replicon types of plasmids carrying fosfomycin resistance genes and other associated resistance genes were investigated.
RESULTS
Twenty-five of the 263 isolates (9.5%) showed resistance to fosfomycin, and 18 (6.8%) were positive for fosA3. None of the isolates was positive for fosA or fosC2. Seventeen of the isolates carrying fosA3 (94%) were CTX-M producers (seven CTX-M-55, five CTX-M-14, and five CTX-M-123), while three (16.7%) were TEM producers (TEM-1).Sixteen (88.9%) fosA3-carrying isolates exhibited multi-drug resistance. The replicon types of the 13 fosA3-carrying plasmids were IncF (n=13), IncHI2 (n=3), IncIl-Ir (n=2), and IncN (n=1).
CONCLUSIONS
Our results indicated that fosA3 could spread through plasmids in S. flexneri isolates, along with the bla(CTX-M) and bla(TEM), which facilitate its quick dispersal. To the best of our knowledge, this is the first report of CTX-M-123-type ESBLs in S. flexneri isolates from patients in China.

Keyword

ESBLs; Plasmids; fosA3; Shigella flexneri; Replicon

MeSH Terms

China*
Drug Resistance, Multiple
Dysentery, Bacillary
Fosfomycin*
Humans
Plasmids
Polymerase Chain Reaction
Public Health
Replicon
Shigella flexneri*
Shigella*
Fosfomycin

Reference

1. Christopher PR, David KV, John SM, Sankarapandian V. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev. 2010; CD006784.

2. Wang XY, Tao F, Xiao D, Lee H, Deen J, Gong J, et al. Trend and disease burden of bacillary dysentery in China (1991-2000). Bull World Health Organ. 2006; 84:561–568. PMID: 16878230.

3. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010; 10:43–50. PMID: 20129148.

4. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008; 46:1069–1077. PMID: 18444827.

5. Samonis G, Maraki S, Rafailidis PI, Kapaskelis A, Kastoris AC, Falagas ME. Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials. Future Microbiol. 2010; 5:961–970. PMID: 20521939.

6. Wachino J, Yamane K, Suzuki S, Kimura K, Arakawa Y. Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob Agents Chemother. 2010; 54:3061–3064. PMID: 20404116.

7. Lee SY, Park YJ, Yu JK, Jung S, Kim Y, Jeong SH, et al. Prevalence of acquired fosfomycin resistance among extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3. J Antimicrob Chemother. 2012; 67:2843–2847. PMID: 22893681.

8. Ho PL, Chan J, Lo WU, Lai EL, Cheung YY, Lau TC, et al. Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates. J Med Microbiol. 2013; 62:1707–1713. PMID: 23988630.

9. Sato N, Kawamura K, Nakane K, Wachino J, Arakawa Y. First detection of fosfomycin resistance gene fosA3 in CTX-M-producing Escherichia coli isolates from healthy individuals in Japan. Microb Drug Resist. 2013; 19:477–482. PMID: 23909549.

10. Tseng SP, Wang SF, Kuo CY, Huang JW, Hung WC, Ke GM, et al. Characterization of fosfomycin resistant extended-spectrum β-lactamase-producing Escherichia coli isolates from human and pig in Taiwan. PLoS One. 2015; 10:e0135864. PMID: 26280832.

11. Hou J, Huang X, Deng Y, He L, Yang T, Zeng Z, et al. Dissemination of the fosfomycin resistance gene fosA3 with CTX-M β-lactamase genes and rmtB carried on IncFII plasmids among Escherichia coli isolates from pets in China. Antimicrob Agents Chemother. 2012; 56:2135–2138. PMID: 22232290.

12. Kim S, Kim J, Kang Y, Park Y, Lee B. Occurrence of extended-spectrum β-lactamases in members of the genus Shigella in the Republic of Korea. J Clin Microbiol. 2004; 42:5264–5269. PMID: 15528724.

13. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. Identification of plasmids by PCR-based replicon typing. J Microbiol Methods. 2005; 63:219–228. PMID: 15935499.

14. Hu GZ, Chen HY, Si HB, Deng LX, Wei ZY, Yuan L, et al. Phenotypic and molecular characterization of TEM-116 extended-spectrum β-lactamase produced by a Shigella flexneri clinical isolate from chickens. FEMS Microbiol Lett. 2008; 279:162–166. PMID: 18093137.

15. Fortineau N, Naas T, Gaillot O, Nordmann P. SHV-type extended-spectrum β-lactamase in a Shigella flexneri clinical isolate. J Antimicrob Chemother. 2001; 47:685–688. PMID: 11328785.

16. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev. 2005; 18:657–686. PMID: 16223952.

17. Taneja N, Mewara A, Kumar A, Verma G, Sharma M. Cephalosporin-resistant Shigella flexneri over 9 years (2001-09) in India. J Antimicrob Chemother. 2012; 67:1347–1353. PMID: 22410619.

18. Xiong Z, Li T, Xu Y, Li J. Detection of CTX-M-14 extended-spectrum β-lactamase in Shigella sonnei isolates from China. J Infect. 2007; 55:e125–e128. PMID: 17767959.

19. Xia S, Xu B, Huang L, Zhao JY, Ran L, Zhang J, et al. Prevalence and characterization of human Shigella infections in Henan Province, China, in 2006. J Clin Microbiol. 2011; 49:232–242. PMID: 21068291.

20. Zhang W, Luo Y, Li J, Lin L, Ma Y, Hu C, et al. Wide dissemination of multidrug-resistant Shigella isolates in China. J Antimicrob Chemother. 2011; 66:2527–2535. PMID: 21859815.

21. He D, Partridge SR, Shen J, Zeng Z, Liu L, Rao L, et al. CTX-M-123, a novel hybrid of the CTX-M-1 and CTX-M-9 Group β-lactamases recovered from Escherichia coli isolates in China. Antimicrob Agents Chemother. 2013; 57:4068–4071. PMID: 23752509.

22. Alrowais H, McElheny CL, Spychala CN, Sastry S, Guo Q, Butt AA, et al. Fosfomycin resistance in Escherichia coli, Pennsylvania, USA. Emerg Infect Dis. 2015; 21:2045–2047. PMID: 26488485.